Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
14.51
-0.21 (-1.43%)
Apr 25, 2025, 10:39 AM EDT - Market open
Arcutis Biotherapeutics Revenue
In the year 2024, Arcutis Biotherapeutics had annual revenue of $196.54M with 229.74% growth. Arcutis Biotherapeutics had revenue of $71.36M in the quarter ending December 31, 2024, with 427.58% growth.
Revenue (ttm)
$196.54M
Revenue Growth
+229.74%
P/S Ratio
9.06
Revenue / Employee
$574,684
Employees
342
Market Cap
1.72B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
ARQT News
- 6 days ago - Arcutis Opportunity To Capitalize On Leadership, Pipeline, And Commercial Assets - Seeking Alpha
- 8 days ago - Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025 - GlobeNewsWire
- 14 days ago - Arcutis Announces Chief Financial Officer Transition - GlobeNewsWire
- 20 days ago - Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 22 days ago - Arcutis and Padagis Agree to Stay Patent Lawsuit - GlobeNewsWire
- 4 weeks ago - Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Top 2 Health Care Stocks That Are Ticking Portfolio Bombs - Benzinga
- 7 weeks ago - Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting - GlobeNewsWire